Alpha 2.0
Login Register
» Authors » Minna Bui

Minna Bui

Explore the profile of Minna Bui including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 118
Followers 0
Related Specialties
Biochemistry
Chemistry
Top 10 Co-Authors
Min Zhong
Emily J Hanan
Johan D Oslob
Jeffrey A Silverman
Chul H Yu
Michael J Romanowski
Wenjin Yang
Wang Shen
Ute Hoch
Marc J Evanchik
Published In
Bioorg Med Chem Lett
J Med Chem
Bioorg Med Chem
ACS Med Chem Lett
Affiliations
Soon will be listed here.
Recent Articles
1.
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy
Jackson J, Shibuya G, Ravishankar B, Adusumilli L, Bradford D, Brockstedt D, et al.
J Med Chem . 2022 Sep; 65(19):12895-12924. PMID: 36127295
General control nonderepressible 2 (GCN2) protein kinase is a cellular stress sensor within the tumor microenvironment (TME), whose signaling cascade has been proposed to contribute to immune escape in tumors....
2.
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors
Hopkins B, Bame E, Bell N, Bohnert T, Bowden-Verhoek J, Bui M, et al.
Bioorg Med Chem . 2021 Jul; 44:116275. PMID: 34314938
Bruton's tyrosine kinase (BTK) is an essential node on the BCR signaling in B cells, which are clinically validated to play a critical role in B-cell lymphomas and various auto-immune...
3.
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity
Leger P, Hu D, Biannic B, Bui M, Han X, Karbarz E, et al.
J Med Chem . 2020 Apr; 63(10):5398-5420. PMID: 32302140
USP7 is a promising target for cancer therapy as its inhibition is expected to decrease function of oncogenes, increase tumor suppressor function, and enhance immune function. Using a structure-based drug...
4.
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens
Hopkins B, Bame E, Bell N, Bohnert T, Bowden-Verhoek J, Bui M, et al.
Bioorg Med Chem . 2019 May; 27(13):2905-2913. PMID: 31138459
Since the approval of ibrutinib for the treatment of B-cell malignancies in 2012, numerous clinical trials have been reported using covalent inhibitors to target Bruton's tyrosine kinase (BTK) for oncology...
5.
Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and...
Gonzalez-Lopez de Turiso F, Hao X, Shin Y, Bui M, Campuzano I, Cardozo M, et al.
J Med Chem . 2016 Jul; 59(15):7252-67. PMID: 27411843
Optimization of the potency and pharmacokinetic profile of 2,3,4-trisubstituted quinoline, 4, led to the discovery of two potent, selective, and orally bioavailable PI3Kδ inhibitors, 6a (AM-0687) and 7 (AM-1430). On...
6.
Synthesis and SAR study of potent and selective PI3Kδ inhibitors
Bui M, Hao X, Shin Y, Cardozo M, He X, Henne K, et al.
Bioorg Med Chem Lett . 2015 Feb; 25(5):1104-9. PMID: 25666823
2,3,4-Substituted quinolines such as (10a) were found to be potent inhibitors of PI3Kδ in both biochemical and cellular assays with good selectivity over three other class I PI3K isoforms. Some...
7.
Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye
Zhong M, Gadek T, Bui M, Shen W, Burnier J, Barr K, et al.
ACS Med Chem Lett . 2014 Jun; 3(3):203-6. PMID: 24900456
LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunological synapse, and augmentation of...
8.
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists
Zhong M, Hanan E, Shen W, Bui M, Arkin M, Barr K, et al.
Bioorg Med Chem Lett . 2010 Nov; 21(1):307-10. PMID: 21109434
This letter describes the structure-activity relationship (SAR) of the 'right-wing' α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists. Novel (S)-substituted heteroaryl-bearing α-amino acids have been identified as replacements of...
9.
Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists
Zhong M, Shen W, Barr K, Arbitrario J, Arkin M, Bui M, et al.
Bioorg Med Chem Lett . 2010 Jul; 20(17):5269-73. PMID: 20655213
This letter describes the discovery of a novel series of tetrahydroisoquinoline (THIQ)-derived small molecules that potently inhibit both human T-cell migration and super-antigen induced T-cell activation through disruption of the...
10.
2-Aminobenzimidazoles as potent Aurora kinase inhibitors
Zhong M, Bui M, Shen W, Baskaran S, Allen D, Elling R, et al.
Bioorg Med Chem Lett . 2009 Aug; 19(17):5158-61. PMID: 19646866
This Letter describes the discovery and key structure-activity relationship (SAR) of a series of 2-aminobenzimidazoles as potent Aurora kinase inhibitors. 2-Aminobenzimidazole serves as a bioisostere of the biaryl urea residue...